What to Watch at Amgen, Merck, Pfizer, and Myriad Genetics This Morning

Amgen, Merck, Pfizer, and Myriad Genetics could loom large in health care headlines today. Here’s why.

Feb 5, 2014 at 9:16AM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Good morning, fellow Foolish investors! Let's take a closer look at four stocks -- Amgen (NASDAQ:AMGN), Merck (NYSE:MRK), Pfizer (NYSE:PFE), and Myriad Genetics (NASDAQ:MYGN) -- which could all loom large in health care headlines this morning.

Amgen and Merck sign a collaboration for a new skin cancer treatment
Amgen and Merck just announced a new collaboration to evaluate an experimental melanoma (skin cancer) treatment combining Amgen's talimogene laherparepvec, an oncolytic immunotherapy, with MK-3475, Merck's investigational anti-PD-1 immunotherapy.

The combination treatment will be evaluated in a phase 1b/2 study of patients with mid- to late-stage melanoma. If the trial is successful, Amgen and Merck's combination therapy could go toe-to-toe against the dominant treatments in skin cancer, such as Roche's Zelboraf and Bristol-Myers Squibb's Yervoy.

Talimogene laherparepvec has shown promise in a phase 3 trial at Amgen as a monotherapy, and MK-3475 is being tested in phase 3 trials comparing the drug to Yervoy. The collaborative trial will be conducted in two parts, and will start in the fall of 2014:



Phase 1b

Determine the safety and tolerability of talimogene laherparepvec combined with MK-3475 in patients with previously untreated/unresected stage IIIb to IVM1a melanoma.

Phase 2

Evaluate the efficacy of the combination treatment versus MK-3475 as a monotherapy in patients with previous untreated/unresected stage IIIB to IVM1c melanoma.

Source: Company press release.

Peak sales estimates for Amgen and Merck's drugs fall in the same range as forecasts for Zelboraf and Yervoy -- between $500 million and $1.5 billion on a melanoma approval alone. However, sales of MK-3475 could eventually spike to $3 billion by 2020 if it is approved for other indications.

The approval of both drugs could help Amgen diversify its portfolio away from Enbrel, which accounted for 25% of its product sales last quarter. For Merck, it represents a way to offset the plunging sales of Singulair, which went off-patent in 2012, and lackluster sales of its diabetes drugs Januvia and Janumet.

Pfizer and Merck explore two new combination therapies using MK-3475
In addition to the new deal with Amgen, Merck also announced a collaboration with Pfizer to combine MK-3475 with two of Pfizer's cancer drugs:




MK-3475 and Inlyta

renal cell carcinoma (RCC)

Phase 1/2

MK-3475 and PF-2566

various anti-tumor responses

Phase 1

Source: Company press release.

The collaboration could help Pfizer grow its cancer portfolio, which is mainly fueled by sales of Xalkori and Inlyta. Last quarter, sales of Xalkori climbed 98% year over year to $89 million while sales of Inlyta soared 117% to $102 million. Although both drugs only account for tiny slivers of Pfizer's top line, analysts believe that Xalkori and Inlyta could eventually hit peak sales of $1.3 billion and $600 million, respectively.

Pfizer's palbociclib is another cancer treatment worth watching. Palbociclib is a targeted breast cancer drug which could treat a much larger population than current standards of care such as Roche's Herceptin (palbociclib could treat up to 60% of the advanced breast cancer population). If approved, palbociclib could generate peak sales of $1.9 billion.

Myriad Genetics to acquire Crescendo Bioscience
Last but not least, Myriad Genetics could do very well this morning after it agreed to purchase Crescendo Bioscience for $270 million in cash. Myriad's second quarter earnings report, which revealed a 43.7% year-over-year jump in its net profit, boosted shares even further. Revenue climbed 37% to $204.1 million. Both Myriad's top and bottom line growth surpassed analyst estimates.

Myriad is best known for its BRCA1 and BRCA2 diagnostic tests, which identify genes which are known to cause breast and ovarian cancer. Several of Myriad's key patents were invalidated last year by the Supreme Court, which has brought competitors such as Quest Diagnostics into the market, but so far Myriad still controls the lion's share of the market.

MYGN Chart

Source: Ycharts.

Acquiring Crescendo, which makes diagnostic tests for inflammatory and autoimmune diseases, will diversify Myriad's portfolio beyond breast cancer. Crescendo's main product, the Vectra DA, is a blood test for patients with rheumatoid arthritis, and generates roughly $10 million in sales per quarter.

The acquisition will dilute Myriad's earnings until 2016, after which it will become earnings accretive. Revenue, through organic and inorganic growth, will remain healthy -- the company now forecasts full-year sales between $740 million and $750 million, compared to its prior forecast of $700 million to $715 million.

Another top stock to watch this morning
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers